Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.44B 3.01B 2.78B 2.58B 4.89B 328B 4.96B 33.23B 12.93B 161B 12.92B 12.64B 559B P/E 2026 *
-46.6x
P/E 2027 * -87.3x
Enterprise Value 3.32B 2.91B 2.68B 2.49B 4.73B 317B 4.79B 32.1B 12.49B 156B 12.48B 12.21B 540B EV / Sales 2026 *
11.6x
EV / Sales 2027 * 9.33x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day+1.46%
1 week+0.47%
Current month+0.23%
1 month+27.22%
3 months+52.70%
6 months+33.46%
Current year+32.39%
1 week 21
Extreme 21
22.8
1 month 15.9
Extreme 15.9
22.8
Current year 12
Extreme 12
22.8
1 year 9.96
Extreme 9.9551
22.8
3 years 2.28
Extreme 2.28
22.8
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
06-28Fiscal year

Executive/Senior Manager

361,358 0.2258%
06-24Sell

Executive/Senior Manager

-5,000 0.0031%
06-24Fiscal year

Director

156,252 0.0976%
Change 5-day change 1-year change 3-year change Capi.($)
+1.46%+0.47%+82.20%+255.37% 3.44B
+1.60%-3.65%+110.81%+149.76% 4.63B
-1.23%+0.78%-26.36%-39.01% 2.04B
-2.78%-0.48%+139.43%-38.47% 1.87B
-0.45%-0.75%+51.04%+247.19% 1.5B
-2.32%-7.67%+120.97%-51.12% 870M
-1.02%-4.60%-9.78%+45.98% 864M
+0.64%+5.55%-34.19%-14.89% 501M
+0.24%-7.16%+3.31% - 473M
-3.20%-17.89% - - 185M
Average -0.71%-2.59%+48.60%+69.35% 1.64B
Weighted average by Cap. +0.06%-1.44%+71.67%+113.17%

Financials

2026 *2027 *
Net sales 287M 252M 232M 215M 408M 27.39B 414M 2.77B 1.08B 13.45B 1.08B 1.05B 46.62B 352M 308M 284M 264M 501M 33.59B 507M 3.4B 1.32B 16.49B 1.32B 1.29B 57.16B
Net income -71.97M -63.03M -58.06M -53.89M -102M -6.87B -104M -695M -270M -3.37B -270M -264M -11.68B -38.02M -33.3M -30.67M -28.47M -54.06M -3.63B -54.79M -367M -143M -1.78B -143M -140M -6.17B
Net Debt -117M -102M -94.18M -87.42M -166M -11.14B -168M -1.13B -439M -5.47B -438M -429M -18.95B -157M -137M -126M -117M -223M -14.93B -226M -1.51B -588M -7.33B -588M -575M -25.41B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-06 US$21.50 +1.46% 2,525,680
26-07-02 US$21.19 -5.27% 3,393,935
26-07-01 US$22.37 +4.29% 3,284,993
26-06-30 US$21.45 +0.23% 3,421,386
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.50USD
Average target price
20.29USD
Spread / Average Target
-5.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock